AMI, an Indazole Derivative, Improves Parkinson’s Disease by Inhibiting Tau Phosphorylation

Zhang, Mao; Zhu, Wenwen; Wang, Haitao; Yu, Hui; Shi-Yi, Lan; Wang, Wenya

doi:10.3389/fnmol.2020.00165

Cited by 2 publications

(1 citation statement)

References 29 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenic factors of PD are not clear, yet genetic factors, age, environmental factors, oxidative stress, and mitochondrial dysfunction may all participate in the degeneration and apoptosis process of dopaminergic (DA) neurons in PD patients. Moreover, the current treatment methods, mainly drug treatment supplemented by surgical treatment, can only improve the symptoms of PD but cannot prevent the progression of the disease, let alone cure the disease [5]. Thus, it has important meaning to explore the occurrence mechanism of PD and seek its potential intervention nodes for the control of the occurrence and development of PD.…”

Section: Introductionmentioning

confidence: 99%

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

Chuanlei

Zhang

Wei

et al. 2021

Neuroimmunomodulation

View full text Add to dashboard Cite

Introduction: LncRNA rhabdomyosarcoma 2-associated transcript (RMST) serves as a key regulator in neural stem cell fate and is involved in the progression of different neurological diseases. In this research, the serum level and clinical value of RMST in Parkinson’s disease (PD) patients were detected, and the underlying mechanism was explored. Methods: Ninety-nine PD patients and 93 healthy individuals were collected for clinical experiments. SH-SY5Y cells were treated with the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) to establish PD cell models. qRT-PCR was used for the detection of mRNA levels. CCK-8 and flow cytometry were used to detect neuronal viability and apoptosis. The target relationship of RMST with miR-15a-5p was confirmed applying luciferase reporter assay. Results: RMST was present at high levels in both serum of PD patients and PD cell models. Serum RMST had a certain clinical value for the diagnosis of PD with the AUC of 0.892 at a cutoff value of 1.225. Serum RMST was positively associated with the levels of TNF-α (r = 0.421, p < 0.001) and IL-1β (r = 0.567, p < 0.001) in PD patients. Knockdown of RMST alleviated the apoptosis and inflammatory response of SH-SY5Y cells induced by MPP+. miR-150-5p was the target gene of RMST and less expressed in the clinical serum samples and PD cell models. Conclusion: Serum RMST serves as a promising biomarker for the diagnosis of PD. RMST downregulation may regulate the occurrence and development of PD through inhibiting neuron cell apoptosis and the release of inflammatory cytokines via targeting miR-150-5p.

show abstract

Section: Introductionmentioning

confidence: 99%

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

Chuanlei

Zhang

Wei

et al. 2021

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

Importance of Indazole against Neurological Disorders

Pal

Sahu

2022

CTMC

View full text Add to dashboard Cite

Indazole is a nitrogen-containing bicyclic compound, having three tautomeric forms: 1H-indazole, 2H-indazole, and 3H-indazole. Mostly, they are considered as 1H-indazole tautomeric form, although it has the potentiality to tautomerism to 2H- and 3H-indazole forms. Indazole is involved in a wide variety of biological and enzymatic processes, therefore they exhibit a series of pharmacological activities. Indazole shows potent activity against neurological disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), mood disorders, etc., by inhibiting different signalling pathways, generation of neurotransmitters and activation of enzyme activity. They effectively prevent neurological diseases by different mechanisms such as by inhibiting the monoamine oxidase (MAO) and kinase enzymes like Glycogen synthase kinase 3 (GSK3), and leucine-rich repeat kinase enzyme 2 (LRRK2). In this article, we have discussed multiple causative strategies of indazole to treat neurological diseases. This has aroused special attention in the discovery of the novel indazoles and their biological activities.

show abstract

AMI, an Indazole Derivative, Improves Parkinson’s Disease by Inhibiting Tau Phosphorylation

Cited by 2 publications

References 29 publications

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

Importance of Indazole against Neurological Disorders

Contact Info

Product

Resources

About